Review
Emergency Medicine
Lindsay Maguire, Timothy Bullard, Linda Papa
Summary: Studies have shown that ketamine may help alleviate treatment-resistant depression and suicidal ideation, and its use in the emergency department may be a promising and safe intervention.
AMERICAN JOURNAL OF EMERGENCY MEDICINE
(2021)
Review
Pharmacology & Pharmacy
Ahmad Shamabadi, Ali Ahmadzade, Alireza Hasanzadeh
Summary: The study aims to systematically identify and evaluate systematic reviews on the efficacy of ketamine in suicidal ideation and behaviors, with a focus on short-term effectiveness. While preliminary evidence suggests positive effects, the quality of many studies is low and long-term effects remain unknown. Common adverse effects of ketamine include transient elevation of pulse rate, blood pressure, dissociation, confusion, blurred vision, nausea, and vertigo.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Review
Clinical Neurology
Adem Tevfik Can, Jules Shamus Mitchell, Megan Dutton, Maxwell Bennett, Daniel Francis Hermens, Jim Lagopoulos
Summary: Suicidality is a prevalent mental health condition that lacks rapid-acting, effective treatment options. There is a need for new treatments to manage suicidal patients and prevent suicide. Understanding the neurobiology underlying suicidal behavior is crucial in developing these treatments.
PSYCHIATRY AND CLINICAL NEUROSCIENCES
(2023)
Review
Psychiatry
Ashley N. Siegel, Joshua D. Di Vincenzo, Elisa Brietzke, Hartej Gill, Nelson B. Rodrigues, Leanna M. W. Lui, Kayla M. Teopiz, Jason Ng, Roger Ho, Roger S. McIntyre, Joshua D. Rosenblat
Summary: This review evaluated the effects of intranasal esketamine and intravenous ketamine on patients with suicidal ideation. Results indicate that ketamine may rapidly reduce suicidal ideation and depressive symptoms, with potential short-lasting effects. The treatment was deemed relatively safe in the short term, and future clinical trials are encouraged to include this study population.
JOURNAL OF PSYCHIATRIC RESEARCH
(2021)
Article
Psychiatry
Marco Aurelio Cigognini, Alia Garrudo Guirado, Denise van de Meene, Monica Andreia Schneider, Monica Sarah Salomon, Vinicius Santana de Alexandria, Juliana Pisseta Adriano, Ana Maria Thaler, Fernando dos Santos Fernandes, Adriana Carneiro, Ricardo Alberto Moreno
Summary: This study aims to evaluate the long-term use of ketamine in the treatment of treatment-resistant depression (TRD) and compare it with active treatment. By assessing efficacy, safety, and tolerability, the study may provide evidence for a new, low-cost, rapid, and feasible approach to depression treatment.
FRONTIERS IN PSYCHIATRY
(2022)
Article
Psychiatry
Yanling Zhou, Chengyu Wang, Xiaofeng Lan, Wei Zheng, Hanqiu Li, Ziyuan Chao, Kai Wu, Roger S. McIntyre, Yuping Ning
Summary: The study found that six infusions of ketamine have potential mood-independent pro-cognitive effects on processing speed in adults with treatment-resistant depression and/or suicidality. The improvement in processing speed was partly independent of the improvement in depressive symptoms.
JOURNAL OF PSYCHIATRIC RESEARCH
(2021)
Article
Psychiatry
Sachin Ahuja, Madeline Brendle, Leo Smart, Claire Moore, Paul Thielking, Reid Robison
Summary: This study aimed to evaluate the clinical characteristics, treatment patterns, clinical outcomes, and adverse events of patients receiving intramuscular (IM) ketamine treatment at an outpatient psychiatric clinic. The results showed significant improvements in depression and anxiety scores throughout the course of IM ketamine treatment, which were maintained during the maintenance treatment phase. Adverse events were rare.
Article
Psychiatry
Denise Beaudequin, Adem T. Can, Monique Jones, Cian Yang, Jennifer K. Scherman, Megan Dutton, Paul Schwenn, Cyrana Gallay Grace Forsyth, Emma Jensen, Daniel F. Hermens, Jim Lagopoulos
Summary: The study found that oral ketamine can rapidly reduce suicidality and depression, but reports on functional and wellbeing outcomes are lacking. Results suggest that reduction in depressive symptoms and suicidal ideation may be necessary but not sufficient for full restoration of function and wellbeing in antisuicidal and antidepressant therapy, including clinical trials.
PSYCHIATRY RESEARCH
(2021)
Article
Clinical Neurology
Megan Dutton, Adem T. Can, Denise Beaudequin, Emma Jensen, Monique Jones, Cyrana C. Gallay, Paul E. Schwenn, Jennifer K. Scherman, Cian Yang, Grace Forsyth, Jim Lagopoulos, Daniel F. Hermens
Summary: This study is the first to examine the effect of ketamine treatment on self-reported stress in adults with chronic suicidality. The results showed that ketamine was able to significantly reduce stress and had a sustained improvement effect. However, the study had limitations such as small sample size and open label design.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Article
Clinical Neurology
Adem T. Can, Paul E. Schwenn, Ben Isbel, Denise Beaudequin, Ana P. Boucas, Megan Dutton, Monique Jones, Cyrana C. Gallay, Grace Forsyth, Maxwell R. Bennett, Jim Lagopoulos, Daniel F. Hermens
Summary: This study investigates the impact of electrophysiological predictors on treatment response time and dose sensitivity in individuals with chronic suicidality treated with oral ketamine. The results show that auditory evoked power bands are helpful in predicting treatment response time, and the differences in beta power may be related to the mechanism of ketamine. These findings are important for the diagnosis, treatment selection, and prediction of treatment outcomes for suicidality.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2023)
Article
Clinical Neurology
Adem T. Can, Daniel F. Hermens, Abdalla Z. Mohamed, Zack Y. Shan, Megan Dutton, Cyrana Gallay, Grace Forsyth, Daniel Jamieson, Jim Lagopoulos
Summary: This study investigates the immediate and prolonged changes in resting-state neural networks after treatment with ketamine, to understand its therapeutic effects. The results show that ketamine can alter brain network connectivity, reduce suicide ideation, and support its use as a treatment for suicidal tendencies.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Article
Psychiatry
Johanna Louise Keeler, Janet Treasure, Hubertus Himmerich, Madeline Brendle, Claire Moore, Reid Robison
Summary: This study reports on the use of intramuscular ketamine or intranasal esketamine for the treatment of depressive symptoms in individuals with comorbid diagnoses of major depressive disorder and anorexia nervosa. The results suggest that (es)ketamine may reduce depressive symptoms in this population, although further research is needed to examine its efficacy, safety, and tolerability.
FRONTIERS IN PSYCHIATRY
(2023)
Article
Psychiatry
Ana Paula Anzolin, Jeferson Ferraz Goularte, Jairo Vinicius Pinto, Paulo Belmonte-de-Abreu, Luciane Nascimento Cruz, Victor Hugo Schaly Cordova, Lucas Sueti Magalhaes, Adriane R. Rosa, Keila Maria Cereser, Marcia Kauer-Sant'Anna
Summary: This study aims to assess the control effect of ketamine on suicidal ideation and behavior in patients with depressive episodes, as well as its impact on psychopathology and inflammatory biomarkers.
FRONTIERS IN PSYCHIATRY
(2023)
Article
Pediatrics
David S. Mathai, Alexis G. McCathern, Andrew G. Guzick, Sophie C. Schneider, Saira A. Weinzimmer, Sandra L. Cepeda, Albert Garcia-Romeu, Eric A. Storch
Summary: Parents show high acceptability towards the use of ketamine in adolescent mood disorders and suicidality, with concerns mainly focused on potential side effects and lack of FDA approval. They prefer short-term applications and less invasive routes for ketamine administration. Factors such as parental history of mental illness and familiarity with psychological treatments predict greater acceptability of ketamine for pediatric mood disorders.
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
(2021)
Article
Psychiatry
Adem T. Can, Daniel F. Hermens, Megan Dutton, Cyrana C. Gallay, Emma Jensen, Monique Jones, Jennifer Scherman, Denise A. Beaudequin, Cian Yang, Paul E. Schwenn, Jim Lagopoulos
Summary: Oral ketamine treatment for chronic suicidality showed a significant reduction in suicidal ideation after 6 weeks, with 69% of participants achieving clinical improvement within the first 6 weeks. This suggests that oral administration could be a feasible and tolerable alternative treatment option for chronic suicidality, with results consistent with IV ketamine trials.
TRANSLATIONAL PSYCHIATRY
(2021)